Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novartis not joining 'frenzy' of weight loss drugs, CEO says
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.
Novartis Skips Weight Loss Drug 'Frenzy,' Focuses on 'Unique Position' for Cancer, Alzheimers, and Parkinsons Treatments
Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated by Novo Nordisk and Eli Lilly. Novartis will instead focus on areas where it can build a “unique position,
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different path. While competitors like Eli Lilly and Novo Nordisk race to capture the booming weight-loss drug market,
Novartis Steers Clear of Weight Loss Drug “Frenzy”
The CEO of Novartis (NYSE:NVS) said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.
1d
on MSN
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
14d
on MSN
Jim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’
We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...
pharmaphorum
2d
Lilly on alert as new Kisqali approval threatens Verzenio
Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...
ENDPOINTS NEWS
2d
Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer
Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...
15d
Top 10 Stocks on Jim Cramer’s Radar
In this article, we’ll explore the Top 10 Stocks on Jim Cramer’s Radar. Jim Cramer often reflects on how he would reform the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback